Form 8-K - Current report:
SEC Accession No. 0001213900-24-042937
Filing Date
2024-05-14
Accepted
2024-05-14 16:10:31
Documents
15
Period of Report
2024-05-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0206046-8k_optimize.htm   iXBRL 8-K 24604
2 PRESS RELEASE, DATED MAY 14, 2024 ea020604601ex99-1_optimize.htm EX-99.1 99435
6 GRAPHIC ex99-1_001.jpg GRAPHIC 4361
  Complete submission text file 0001213900-24-042937.txt   316729

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE oprx-20240514.xsd EX-101.SCH 3021
4 XBRL LABEL FILE oprx-20240514_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE oprx-20240514_pre.xml EX-101.PRE 22363
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0206046-8k_optimize_htm.xml XML 3671
Mailing Address 260 CHARLES STREET SUITE 302 WALTHAM MA 02453
Business Address 260 CHARLES STREET SUITE 302 WALTHAM MA 02453 248-651-6558
OptimizeRx Corp (Filer) CIK: 0001448431 (see all company filings)

EIN.: 261265381 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38543 | Film No.: 24944426
SIC: 7389 Services-Business Services, NEC
(CF Office: 07 Trade & Services)